Abstract:Propose: Instant blood-mediated inflammatory reaction (IBMIR) causes significant peri-transplant islet damage following intraportal transplantation. IBMIR is initiated and perpetuated by a cascade of cellular and soluble innate immune responses, including high-mobility group box 1, tissue factor, macrophage chemoattractant protein-1, and interleukin-1β. Thrombomodulin (TM) regulates coagulation and suppresses inflammatory functions of neutrophils and macrophages while CD47 inhibits phagocytosis by macrophages, reducing inflammation and tissue damage. The main objective of this study was to exploit the immunomodulatory efficacy of these two molecules to mitigate IBMIR. Method: Pancreatic islets were biotinylated, followed by transient and positional display on their surface novel forms of TM (SA-TM) and CD47 (SA-CD47) chimeric with a modified form of streptavidin by taking the advantage of strong affinity between biotin and streptavidin. The viability and function of the engineered islets as well as their ability to mitigate IBMIR were assessed. Co-engineered islets were transplanted intraportally into streptozotocin diabetic syngeneic recipients (150 IEQ/mouse). Unmodified islets or islets engineered with SA-TM served as control. Blood glucose levels were monitored and graft function was assessed using an intraperitoneal glucose tolerance test. Flow cytometry and transcriptomic analysis were conducted on graft recipients at different times post-transplantation. Results: Islets were successfully engineered with SA-TM/SA-CD47 combination without affecting their viability and function. SA-TM/SA-CD47 on rat splenocytes inhibited phagocytosis by mouse macrophages in vitro. Similarly, bone marrow cells engineered with SA-TM/SA-CD47 were resistant to clearance in allogeneic hosts. In an ex vivo blood loop assay, SA-TM/SA-CD47 prevented islet damage associated with the down-regulation of various inflammatory mediators driving IBMIR. In a syngeneic minimal mass model of intraportal islet transplantation, SA-TM/SA-CD47-engineered islets had enhanced engraftment as compared with SA-TM-engineered islets or unmodified islets. The enhanced engraftment was associated with a significant decrease in intragraft proinflammatory cells and transcritps involved in IBMIR. Conclusion: Engineering islets to codisplay on their surface SA-TM and SA-CD47 molecules as regulators of innate immune responses effectively inhibits peri-transplant islet graft loss with implications for both autologous and allogeneic islet transplantation. Funded in parts by NIH R01AI121281 award.

Effect of Thioketal Antioxidants on Islet Cell Transplantation

1729-P: Role of ß-Cell Senescence in Islet Transplantation

Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Biological hypoxia in pre-transplant human pancreatic islets induces transplant failure in diabetic mice

Co-transplantation of Islets-Laden Microgels and Biodegradable O2-Generating Microspheres for Diabetes Treatment

Immunoprotection Strategies in β‐Cell Replacement Therapy: A Closer Look at Porcine Islet Xenotransplantation

In Vitro and In Vivo Improvement of Islet Quality and Transplantation Successes following Islet Treatment with Biomaterials in Diabetic Rats

Immune-Protective Formulations and Process Strategies for Improved Survival and Function of Transplanted Islets

Long-term Tolerance to Islet Transplantation via Targeted Reduction of beta cell-specific T cells.

Regulated Cell Death Seen through the Lens of Islet Transplantation

Inflammatory and hypoxic stress-induced islet exosomes released during isolation are associated with poor transplant outcomes in islet autotransplantation

Co-transplantation of human adipose-derived mesenchymal stem cells with neonatal porcine islets within a prevascularized subcutaneous space augments the xenograft function

A Strategy to Simultaneously Cure Type 1 Diabetes and Diabetic Nephropathy by Transplant of Composite Islet-Kidney Grafts

201.1: Co-engineering Pancreatic Islets with Novel Forms of Thrombomodulin and CD47 As an Effective Means of Mitigating Instant Blood-Mediated Inflammatory Reaction

A novel prevascularized tissue-engineered chamber as a site for allogeneic and xenogeneic islet transplantation to establish a bioartificial pancreas

Islet Transplantation: Current Limitations and Challenges for Successful Outcomes

Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes

Phase-changing citrate macromolecule combats oxidative pancreatic islet damage, enables islet engraftment and function in the omentum

The future treatment for type 1 diabetes: Pig islet- or stem cell-derived β cells?